Perfluortetradecaanzuur

Perfluorotetradecanoic acid (PFTeDA) is a PPARγ inhibitor. Perfluorotetradecanoic acid binds to human PPARγ ligand binding domain with IC50 of 22.8 μM, Kd of 157.8 μM. Perfluorotetradecanoic acid inhibits the function of Leydig cells by inducing oxidative stress and apoptosis. Perfluorotetradecanoic acid stimulates corticosterone biosynthesis but inhibits aldosterone production[1][2][3].

376-06-7

PFTeDA

12352211

H302+H332, H351, H360, H362, H372

Apoptosis; PPAR

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Endocrinology

98.0

O=C(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(F)F)F)F)F)F)F)F)F)F)F)F)F)F)O

C14HF27O2

714.11

H302+H332, H351, H360, H362, H372

[1]Zhang L, et al. Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ. Toxicol Appl Pharmacol. 2014 Sep 15;279 (3) :275-283.|[2]Tang Y, et al. Leydig cell function in adult male rats is disrupted by perfluorotetradecanoic acid through increasing oxidative stress and apoptosis. Environ Toxicol. 2022 Jul;37 (7) :1790-1802.|[3]Ying Y, et al. Perfluorotetradecanoic acid exposure to adult male rats stimulates corticosterone biosynthesis but inhibits aldosterone production. Environ Toxicol. 2024 May;39 (5) :2610-2622.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-W073128/Perfluorotetradecanoic-acid-SDS-MedChemExpress.pdf

Reference compound1

No Development Reported